After each hospitalization, patients are at increased risk of death, rehospitalization,
and other poor
outcomes1-3

HFpEF=heart failure with preserved ejection fraction; LVEF=left ventricular ejection fraction.
†HFpEF with LVEF below normal defined as LVEF 41% to 60%.4
*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.9
Help keep patients out of the hospital
ENTRESTO® reduced total heart failure hospitalizations and CV death9-11

For the primary end point, reduction in the composite of total (first and recurrent) HF hospitalizations and CV death, ENTRESTO did not achieve statistical significance vs valsartan (RR 0.87; 95% CI: 0.75, 1.01; P=0.06).
ARR=absolute rate reduction; CV=cardiovascular; LVEF=left ventricular ejection fraction; RR=rate ratio; RRR=relative rate reduction.
‡The median LVEF was 57%. LVEF is a variable measure that can change over time, and the normal range differs according to patient characteristics and method of assessment.9
§Event rate per 100 patient years.
ENTRESTO reduced total heart failure hospitalizations vs valsartan9,11
PARAGON-HF: Total heart failure hospitalizations in patients with LVEF at or below the median‖

ARR=absolute rate reduction; HF=heart failure; HR=hazard ratio; LVEF=left ventricular ejection fraction; RR=rate ratio; RRR=relative rate reduction.
‖The median LVEF was 57%. LVEF is a variable measure that can change over time, and the normal range differs according to patient characteristics and method of assessment.9
¶Event rate per 100 patient years.
PARAGON-HF STUDY DESIGN
PARAGON-HF study design9
PARAGON-HF was a randomized, double-blind, active-controlled trial comparing ENTRESTO to valsartan in 4796 adult patients with symptomatic (NYHA Class II–IV) HFpEF (LVEF ≥45%), elevated levels of natriuretic peptides, and structural heart disease. After completing the run-in period with valsartan followed by ENTRESTO, patients entered the double-blind period and were randomly assigned (1:1) to ENTRESTO 97/103 mg BID (n=2419) or valsartan 160 mg BID (n=2403). The median follow-up duration was 35 months, and patients were treated for up to 4.7 years. For the primary end point, reduction in the composite of total (first and recurrent) HF hospitalizations and CV death, ENTRESTO did not achieve statistical significance vs valsartan (RR 0.87; 95% CI: 0.75, 1.01; P=0.06).
BID=twice daily; HFpEF=heart failure with preserved ejection fraction; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association.

See the proven safety profile of ENTRESTO